APA (7th ed.) Citation

Pacey, S., Blackhall, F., Garcia-Corbacho, J., Lipplaa, A., Fusi, A., Kumar, S., . . . Talbot, D. (2016). A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors. Oxford University Press.

Chicago Style (17th ed.) Citation

Pacey, S., et al. A Phase I Dose Escalation Study of the Tolerability of the Oral VEGFR and EGFR Inhibitor Vandetanib in Combination with the Oral MEK1/2 Inhibitor Selumetinib in Solid Tumors. Oxford University Press, 2016.

MLA (9th ed.) Citation

Pacey, S., et al. A Phase I Dose Escalation Study of the Tolerability of the Oral VEGFR and EGFR Inhibitor Vandetanib in Combination with the Oral MEK1/2 Inhibitor Selumetinib in Solid Tumors. Oxford University Press, 2016.